CD38

ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 · P28907 · CD38 on Sugi Atlas →

18,332 patent compounds predicted against CD38, 7,798 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL1824864	0.55	17/20
SCHEMBL527991	0.51	17/20
SCHEMBL1823996	0.57	16/20
SCHEMBL527683	0.48	15/20
SCHEMBL1642074	0.52	14/20
Delphinidin (SCHEMBL22370)	1.00	12/20
Delphinidin (SCHEMBL22369)	0.97	12/20
Peonidin (SCHEMBL20017)	1.00	11/20
Pelargonidin (SCHEMBL20592)	1.00	11/20
Cyanidin (SCHEMBL20799)	1.00	11/20
Petunidin (SCHEMBL21650)	1.00	11/20
Luteolinidin (SCHEMBL676808)	1.00	11/20
Peonidin (SCHEMBL20016)	0.97	11/20
Petunidin (SCHEMBL21649)	0.97	11/20
Cyanidin (SCHEMBL156277)	0.97	11/20
Cyanidin (SCHEMBL608392)	0.97	11/20
Luteolinidin (SCHEMBL676807)	0.97	11/20
Cyanidin (SCHEMBL1644900)	0.97	11/20
Pelargonidin (SCHEMBL20591)	0.97	11/20
Peonidin (SCHEMBL2560105)	0.95	11/20

Clinical trials — most relevant to CD38 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Daratumumab Intensified Treatment to Eligible MM New Patients CTD-Dara Induction, Follow by Dara Consolidation	PHASE3	UNKNOWN
A Study to Evaluate the Safety and Efficacy of CD388 for Prevention of Influenza	PHASE3	ACTIVE_NOT_RECRUITING
A Phase I/II Study to Assess the Safety and Tolerability of APO866 for the Treatment of Refractory B-CLL	PHASE1/PHASE2	COMPLETED
Anti-CD38 Monoclonal Antibody Combined With Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)	PHASE2	RECRUITING
The Safety and Efficacy of Daratumumab in Patients With Refractory Aplastic Anemia	PHASE1/PHASE2	NOT_YET_RECRUITING
Study of Daratumumab in Combination With Dexamethasone in Resistant or Refractory Multiple Myeloma	PHASE2	COMPLETED
Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma, Plasmablastic Lymphoma, and Multicentric Castleman Disease	PHASE2	RECRUITING
A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma	PHASE2	ACTIVE_NOT_RECRUITING
Daratumumab in Combination With ATRA	PHASE1/PHASE2	COMPLETED
A Study of APO866 for the Treatment of Cutaneous T-cell Lymphoma	PHASE2	COMPLETED
Anti-CD38 Antibody Treating Evans Syndrome	PHASE2	RECRUITING
A Study of Daratumumab in Patients With Relapsed or Refractory Waldenström Macroglobulinemia	PHASE2	COMPLETED
Daratumumab as Maintenance After Peripheral Blood Stem Cell Transplantation From HLA-identical or Haploidentical Family Donor in the Treatment of Refractory or Relapsed Multiple Myeloma: a Phase 2 Trial	PHASE2	WITHDRAWN
Rituximab Combining Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)	PHASE2	RECRUITING
Tracing the Metabolic Flux of Orally Administered NAD+ Precursors	PHASE1	RECRUITING
A Clinical Study of SCTC21C in Participants With CD38+ Hematologic Malignancies	PHASE1	RECRUITING
Study of Bromodomain and Extra-Terminal Protein (BET) Inhibitor RO6870810 as Mono- and Combination Therapy in Advanced Multiple Myeloma	PHASE1	COMPLETED
Phase 1a Single Ascending Dose Study of MIB-725 in Healthy Adults	PHASE1	RECRUITING
The Safety of Repurposing Daratumumab for Relapsed or Refractory Autoimmune Antibody Mediated Hemolytic Anemia	PHASE1	COMPLETED
Veliparib, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Non-Hodgkin Lymphoma	PHASE1	ACTIVE_NOT_RECRUITING
ABT-888 Plus Metronomic Cyclophosphamide to Treat Cancer	PHASE1	COMPLETED
Multi-center, Open-label, Phase 1b Study in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)	PHASE1	COMPLETED
FT538 in Combination With Daratumumab in AML Acute Myeloid Leukemia	PHASE1	COMPLETED
Daratumumab and Ibrutinib in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia	PHASE1	COMPLETED
Clinical Study of CD38 CAR-T Cells in the Treatment of Hematological Malignancies	EARLY_PHASE1	UNKNOWN
Daratumumab for Familial Cerebral Cavernous Malformations: A Single-Arm Safety and Efficacy Study	EARLY_PHASE1	NOT_YET_RECRUITING
Biomarkers to Predict the Response to Pembrolizumab in Chinese NSCLC Patients	nan	COMPLETED
How Sirtuin Levels Change During Behçet Disease	nan	UNKNOWN
Project SIRT6 Activator	nan	RECRUITING
Effect of B-cell Depleting Therapies on PLA2R-specific B Cells in Patients With Membranous Nephropathy	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a CD38 binder may also engage these)

Protein	Name	Similarity
Q9MZ03	—	1.000	Q9MZ03 →
P56528	—	0.997	P56528 →
Q5VAN0	—	0.996	Q5VAN0 →
Q8AYW1	—	0.994	Q8AYW1 →
Q8AYY5	—	0.993	Q8AYY5 →
Q64244	—	0.993	Q64244 →
P10260	—	0.993	P10260 →
P16837	—	0.992	P16837 →
A0A0F7YYX3	—	0.992	A0A0F7YYX3 →
Q6NVG5	—	0.992	Q6NVG5 →
A0A7H0DN66	—	0.992	A0A7H0DN66 →
E1C7U0	—	0.992	E1C7U0 →
A4IFN2	—	0.991	A4IFN2 →
Q2YDM0	—	0.991	Q2YDM0 →
Q64277	—	0.991	Q64277 →
Q66653	—	0.991	Q66653 →
Q6NRW0	—	0.991	Q6NRW0 →
P07968	—	0.991	P07968 →
P08362	—	0.991	P08362 →
Q10008	—	0.991	Q10008 →
P11323	—	0.991	P11323 →
Q0P4G8	—	0.991	Q0P4G8 →
Q8JSZ3	—	0.991	Q8JSZ3 →
A5WWB6	—	0.990	A5WWB6 →
P29169	—	0.990	P29169 →
Q8B115	—	0.990	Q8B115 →
Q67205	—	0.990	Q67205 →
Q77ZL5	—	0.990	Q77ZL5 →
Q77ZK8	—	0.990	Q77ZK8 →
P0DOS8	—	0.990	P0DOS8 →